{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:49:40Z","timestamp":1792586980815,"version":"4.5.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Observational studies report that prolonged infusions of piperacillin\u2010tazobactam may enable the achievement of an optimal clinically targeted free drug concentration above the minimum inhibitory concentration (fT\u2009&gt;\u2009MIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess the feasibility of a randomized controlled trial (RCT) comparing standard to prolonged infusions of piperacillin\u2010tazobactam in the obese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this open\u2010label RCT, patients with a body mass index (BMI) of 30\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or higher who initiated piperacillin\u2010tazobactam were recruited and randomly assigned to receive either standard or prolonged infusions of the antibiotic. Feasibility and safety outcomes were assessed. A blood sample was collected 24\u2009h after the intervention to measure total piperacillin concentrations, with an exploratory aim of determining the proportion of patients who achieved 100% fT\u2009&gt;\u2009MIC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 45 patients were recruited at a rate of 7.2 patients per month with a consent rate of 42.1%, achieving these feasibility objectives. Adherence to blood sampling was 77.8%, below the 80% objective. On an exploratory basis, the proportion of patients who achieved 100% fT\u2009&gt;\u2009MIC 24\u2009h postintervention was 64.3% in the prolonged\u2010infusion group and 55.6% in the standard\u2010infusion group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.725). There was no significant difference in the safety outcomes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.756).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This first RCT evaluating prolonged infusions of piperacillin\u2010tazobactam in the obese population demonstrated the feasibility of the protocol. Although not statistically significant, the results suggest a favorable trend for fT\u2009&gt;\u2009MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      Clinical trial registration:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06690905&amp;data=05%7C02%7Csabrina.larocque.1%40umontreal.ca%7Cab8a057d40e64490552c08dd04dc39b7%7Cd27eefec2a474be7981e0f8977fa31d8%7C1%7C0%7C638672066085232706%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=AFiWX8RamSZc3ehCvVi3jbAA8yaBiwe%2FLzV9SX3424Y%3D&amp;reserved=0\">NCT #06690905<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70116","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:35:58Z","timestamp":1792586158000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin\u2010Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO\u2010OBESITY Trial)"],"prefix":"10.1111","volume":"40","author":[{"given":"Sabrina","family":"Larocque","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Fournier","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Brasseur\u2010Masse","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britanny","family":"Bernard","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3320-0900","authenticated-orcid":false,"given":"Guiva","family":"Annane","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"},{"name":"STP2 Laboratory, Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-7866","authenticated-orcid":false,"given":"Louis\u2010Patrick","family":"Haraoui","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases Universit\u00e9 de Sherbrooke  Sherbrooke Qu\u00e9bec Canada"},{"name":"Charles\u2010Le Moyne Research Center Centre int\u00e9gr\u00e9 de sant\u00e9 et de services sociaux de la Mont\u00e9r\u00e9gie\u2010Centre  Greenfield Park Qu\u00e9bec Canada"},{"name":"Humans and the Microbiome Program Canadian Institute for Advanced Research  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Ouyahia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre int\u00e9gr\u00e9 de sant\u00e9 et de services sociaux de la Mont\u00e9r\u00e9gie\u2010Centre  Greenfield Park Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9303-8862","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"},{"name":"STP2 Laboratory, Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Qu\u00e9bec Canada"},{"name":"Research Center CHU Sainte\u2010Justine  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-1585","authenticated-orcid":false,"given":"Beno\u00eet","family":"Crevier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre int\u00e9gr\u00e9 de sant\u00e9 et de services sociaux de la Mont\u00e9r\u00e9gie\u2010Centre  Greenfield Park Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"World Health Organization \u201cObesity and Overweight \u201d Published May 7 2025. Accessed May 29 2025 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00316\u20104"},{"key":"e_1_2_13_4_1","unstructured":"World Obesity \u201cWorld Obesity Atlas 2024 \u201d Published March 2024. Accessed February 20 2025 https:\/\/data.worldobesity.org\/publications\/?cat=22."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010025\u201001592\u20103"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.505"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199447030\u201000008"},{"key":"e_1_2_13_8_1","unstructured":"Pfizer \u201cZosyn Product Monograph. Food and Drug Administration \u201d Updated May 2017. Accessed October 23 2024. ZOSYN (Piperacillin and Tazobactam) for Injection."},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091380"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2842"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134\u2010021\u201006506\u2010y"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2014.15"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318\u2010021\u201000677\u20101"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa128"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.259"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.9.1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K256"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.09.004"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01276\u201016"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002287"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150205"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102024\u2010081123"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001284"},{"key":"e_1_2_13_27_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2025"},{"key":"e_1_2_13_28_1","volume-title":"Guide d'utilisation des antibiotiques de l'H\u00f4pital Charles\u2010Le Moyne","author":"Al\u2010Bachari H.","year":"2023"},{"key":"e_1_2_13_29_1","volume-title":"The Sanford Guide to Antimicrobial Therapy 2024","author":"Gilbert D. N.","year":"2024"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.01.018"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2769"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1324"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.70116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:36:01Z","timestamp":1792586161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/fcp.70116"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70116","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70116"}}